{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:21:08Z","timestamp":1780636868088,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017540","name":"NHLBI Division of Intramural Research","doi-asserted-by":"publisher","award":["R01HL123064"],"award-info":[{"award-number":["R01HL123064"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rheumatoid arthritis (RA)-associated lung disease (LD) associates with significantly increased morbidity and mortality. Although oxidative stress plays an important role in the inflammatory responses in other forms of lung disease, minimal work has evaluated its role in RA-LD. The current work examines the relationship between the anti-oxidant HDL-associated enzyme paraoxonase-1 (PON1), the PON1 Q192R polymorphism, and a targeted oxylipin panel with RA-LD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was conducted as a retrospective chart review of a longitudinal single-center cohort of 250 RA patients. CT scans of the chest were reviewed by the interpreting radiologist and classified as small airways disease (SAD), interstitial lung disease (ILD), and bronchiectasis. PON1 activity was measured by its lactonase, arylesterase, and paraoxonase functions. The PON1 Q192R polymorphism and a targeted lipidomics panel were performed as previously reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>43.2% of the 250 RA patient cohort (<jats:italic>n<\/jats:italic>\u2009=\u2009108) had available CT scans, including 48 patients (44.4%) with SAD, 27 patients (25.0%) with bronchiectasis, and 16 patients (14.8%) with ILD. Patients with SAD had significantly lower baseline PON1 activity by its arylesterase, and lactonase functions, as well as higher 15-HETE, LTB4, and PGE2 levels compared to those without SAD. These predictors of SAD remained significant after multivariate analysis including known risk factors for RA-LD. Suppressed PON1 activity also correlated with higher levels of 15-HETE and 12-HETE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In a single-center RA cohort, suppressed baseline PON1 activity and elevation in the oxylipins 15-HETE, LTB4, and PGE2 predicted the presence of RA-SAD in longitudinal follow-up.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\" colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Small airways disease (SAD) was present in 44.4% of this rheumatoid arthritis (RA) cohort.<\/jats:italic><jats:italic>\u2022 Patients with SAD had significantly lower baseline PON1 activity, as well as higher levels of the oxylipins 15-HETE, LTB4, and PGE2 levels compared to those without SAD.<\/jats:italic><jats:italic>\u2022 Further work is warranted to confirm these findings and further define the role of PON1 and lipid oxidation in RA lung disease.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-022-06375-w","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T18:04:03Z","timestamp":1663869843000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"42","author":[{"given":"Amir A.","family":"Razmjou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani","family":"Shahbazian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"6375_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS et al (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"6375_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41584-019-0275-x","volume":"15","author":"D Wang","year":"2019","unstructured":"Wang D, Zhang J, Lau J, Wang S, Taneja V, Matteson EL et al (2019) Mechanisms of lung disease development in rheumatoid arthritis. Nat Rev Rheumatol 15(10):581\u2013596","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"6375_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40674-020-00160-z","volume":"6","author":"S Huang","year":"2020","unstructured":"Huang S, Kronzer VL, Dellaripa PF, Deane KD, Bolster MB, Nagaraja V et al (2020) Rheumatoid arthritis-associated interstitial lung disease: current update on prevalence, risk factors, and pharmacologic treatment. Curr Treatm Opt Rheumatol 6(4):337\u2013353","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"5","key":"6375_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11926-012-0271-5","volume":"14","author":"C Charles-Schoeman","year":"2012","unstructured":"Charles-Schoeman C (2012) Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep 14(5):455\u2013462","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"6375_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/01.ATV.21.4.473","volume":"21","author":"PN Durrington","year":"2001","unstructured":"Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21(4):473\u2013480","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"6375_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/ATVBAHA.107.141283","volume":"27","author":"NM Gharavi","year":"2007","unstructured":"Gharavi NM, Gargalovic PS, Chang I, Araujo JA, Clark MJ, Szeto WL et al (2007) High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory. Arterioscler Thromb Vasc Biol 27(6):1346\u20131353","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"6375_CR7","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1002\/art.38118","volume":"65","author":"C Charles-Schoeman","year":"2013","unstructured":"Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, Fitzgerald J, Ranganath VK et al (2013) Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 65(11):2765\u20132772","journal-title":"Arthritis Rheum"},{"issue":"9","key":"6375_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","volume":"107","author":"DH Solomon","year":"2003","unstructured":"Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9):1303\u20131307","journal-title":"Circulation"},{"issue":"2","key":"6375_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.amjcard.2003.09.037","volume":"93","author":"LM Fischer","year":"2004","unstructured":"Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR (2004) Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 93(2):198\u2013200","journal-title":"Am J Cardiol"},{"issue":"6","key":"6375_CR10","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/art.20306","volume":"50","author":"M Boers","year":"2004","unstructured":"Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O\u2019Dell J, Pincus T (2004) Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum 50(6):1734\u20131739","journal-title":"Arthritis Rheum"},{"issue":"3","key":"6375_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/art.20878","volume":"52","author":"H Maradit-Kremers","year":"2005","unstructured":"Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722\u2013732","journal-title":"Arthritis Rheum"},{"issue":"12","key":"6375_CR12","first-page":"2562","volume":"26","author":"S Wallberg-Jonsson","year":"1999","unstructured":"Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S (1999) Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 26(12):2562\u20132571","journal-title":"J Rheumatol"},{"issue":"9","key":"6375_CR13","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/art.40532","volume":"70","author":"Z Yu","year":"2018","unstructured":"Yu Z, Yang N, Everett BM, Frits M, Iannaccone C, Coblyn J et al (2018) Impact of changes in inflammation on estimated ten-year cardiovascular risk in rheumatoid arthritis. Arthritis Rheumatol 70(9):1392\u20131398","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"6375_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0022-2275(20)33462-3","volume":"41","author":"M Navab","year":"2000","unstructured":"Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD et al (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41(9):1495\u20131508","journal-title":"J Lipid Res"},{"issue":"9","key":"6375_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S0022-2275(20)33461-1","volume":"41","author":"M Navab","year":"2000","unstructured":"Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L et al (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41(9):1481\u20131494","journal-title":"J Lipid Res"},{"issue":"1\u20132","key":"6375_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0014-5793(91)80962-3","volume":"286","author":"MI Mackness","year":"1991","unstructured":"Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286(1\u20132):152\u2013154","journal-title":"FEBS Lett"},{"issue":"2","key":"6375_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364(2):127\u2013135","journal-title":"N Engl J Med"},{"issue":"3","key":"6375_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10067-017-3896-y","volume":"37","author":"C Charles-Schoeman","year":"2018","unstructured":"Charles-Schoeman C, Meriwether D, Lee YY, Shahbazian A, Reddy ST (2018) High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritis. Clin Rheumatol 37(3):615\u2013622","journal-title":"Clin Rheumatol"},{"issue":"10","key":"6375_CR19","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1002\/art.24802","volume":"60","author":"C Charles-Schoeman","year":"2009","unstructured":"Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D et al (2009) Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 60(10):2870\u20132879","journal-title":"Arthritis Rheum"},{"issue":"10","key":"6375_CR20","doi-asserted-by":"publisher","first-page":"e0164564","DOI":"10.1371\/journal.pone.0164564","volume":"11","author":"JY Kim","year":"2016","unstructured":"Kim JY, Lee EY, Park JK, Song YW, Kim JR, Cho KH (2016) Patients with rheumatoid arthritis show altered lipoprotein profiles with dysfunctional high-density lipoproteins that can exacerbate inflammatory and atherogenic process. PLoS One 11(10):e0164564","journal-title":"PLoS ONE"},{"key":"6375_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.atherosclerosis.2016.06.009","volume":"251","author":"E Botta","year":"2016","unstructured":"Botta E, Merono T, Saucedo C, Martin M, Tetzlaff W, Sorroche P et al (2016) Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis. Atherosclerosis 251:438\u2013444","journal-title":"Atherosclerosis"},{"issue":"2","key":"6375_CR22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.atherosclerosis.2014.09.034","volume":"237","author":"L Gomez Rosso","year":"2014","unstructured":"Gomez Rosso L, Lhomme M, Merono T, Sorroche P, Catoggio L, Soriano E et al (2014) Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation. Atherosclerosis 237(2):652\u2013660","journal-title":"Atherosclerosis"},{"issue":"6","key":"6375_CR23","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/art.34363","volume":"64","author":"J Watanabe","year":"2012","unstructured":"Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G et al (2012) Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 64(6):1828\u20131837","journal-title":"Arthritis Rheum"},{"key":"6375_CR24","unstructured":"Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A et al (2020) Relationship between paraoxonase-1 genotype, activity, and major adverse cardiovascular events in patients with rheumatoid arthritis receiving tofacitinib [abstract]. Arthritis Rheumatol 72(suppl 10)"},{"issue":"35","key":"6375_CR25","doi-asserted-by":"publisher","first-page":"13032","DOI":"10.1073\/pnas.0405292101","volume":"101","author":"C Bergt","year":"2004","unstructured":"Bergt C, Pennathur S, Fu X, Byun J, O\u2019Brien K, McDonald TO et al (2004) The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 101(35):13032\u201313037","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"6375_CR26","doi-asserted-by":"publisher","first-page":"16848","DOI":"10.1038\/s41598-020-74016-w","volume":"10","author":"C Charles-Schoeman","year":"2020","unstructured":"Charles-Schoeman C, Wang J, Shahbazian A, Lee YY, Wang X, Grijalva V et al (2020) Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice. Sci Rep 10(1):16848","journal-title":"Sci Rep"},{"issue":"3","key":"6375_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/08923973.2013.797993","volume":"35","author":"L Golmanesh","year":"2013","unstructured":"Golmanesh L, Bahrami F, Pourali F, Vahedi E, Wahhabaghai H, Mehrani H et al (2013) Assessing the relationship of paraoxonase-1 Q192R polymorphisms and the severity of lung disease in SM-exposed patients. Immunopharmacol Immunotoxicol 35(3):419\u2013425","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"2","key":"6375_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5152\/eurasianjmed.2019.19122","volume":"52","author":"N Sarioglu","year":"2020","unstructured":"Sarioglu N, Bilen C, Cevik C, Gencer N (2020) Paraoxonase activity and phenotype distribution in patients with chronic obstructive pulmonary disease. Eurasian J Med 52(2):161\u2013165","journal-title":"Eurasian J Med"},{"issue":"2","key":"6375_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0009-2797(01)00225-3","volume":"137","author":"L Rodrigo","year":"2001","unstructured":"Rodrigo L, Hern\u00e1ndez AF, L\u00f3pez-Caballero JJ, Gil F, Pla A (2001) Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 137(2):123\u2013137","journal-title":"Chem Biol Interact"},{"issue":"5","key":"6375_CR30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.freeradbiomed.2008.12.005","volume":"46","author":"Y Umemoto","year":"2009","unstructured":"Umemoto Y, Takata K, Hori M, Sato K, Nakagawa K (2009) Identification of paraoxonase-1 in induced sputum from healthy volunteers. Free Radic Biol Med 46(5):699","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"6375_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/jcb.26242","volume":"119","author":"WQ Chen","year":"2018","unstructured":"Chen WQ, Xie ZZ, Wang X, Zhao JH, Hu Q, Chen YH et al (2018) Influences of PON1 on airway inflammation and remodeling in bronchial asthma. J Cell Biochem 119(1):793\u2013805","journal-title":"J Cell Biochem"},{"issue":"6","key":"6375_CR32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/art.41631","volume":"73","author":"KJ Polinski","year":"2021","unstructured":"Polinski KJ, Bemis EA, Yang F, Crume T, Demoruelle MK, Feser M et al (2021) Association of lipid mediators with development of future incident inflammatory arthritis in an anti-citrullinated protein antibody-positive population. Arthritis Rheumatol 73(6):955\u2013962","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"6375_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","volume":"43","author":"C Roubille","year":"2014","unstructured":"Roubille C, Haraoui B (2014) Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 43(5):613\u2013626","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"6375_CR34","doi-asserted-by":"publisher","first-page":"102830","DOI":"10.1016\/j.autrev.2021.102830","volume":"20","author":"EF Vicente-Rabaneda","year":"2021","unstructured":"Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Casta\u00f1eda S et al (2021) Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmun Rev 20(6):102830","journal-title":"Autoimmun Rev"},{"key":"6375_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fmed.2019.00238","volume":"6","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R (2019) Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment. Front Med (Lausanne) 6:238","journal-title":"Front Med (Lausanne)"},{"key":"6375_CR36","doi-asserted-by":"crossref","unstructured":"McInnes IB, Kaplan I, Boy M, Riese R, Zuckerman A, Gruben D et al (2013) FRI0137\u2005Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis. Ann Rheum Dis 72(Suppl 3):A416-A","DOI":"10.1136\/annrheumdis-2013-eular.1264"},{"key":"6375_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2018.04.003","volume":"275","author":"C Charles-Schoeman","year":"2018","unstructured":"Charles-Schoeman C, Gugiu GB, Ge H, Shahbazian A, Lee YY, Wang X et al (2018) Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. Atherosclerosis 275:107\u2013114","journal-title":"Atherosclerosis"},{"issue":"1","key":"6375_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.39833","volume":"69","author":"C Charles-Schoeman","year":"2017","unstructured":"Charles-Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR et al (2017) Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheumatol 69(1):46\u201357","journal-title":"Arthritis Rheumatol"}],"updated-by":[{"DOI":"10.1007\/s10067-023-06768-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06375-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T20:01:50Z","timestamp":1700424110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6375"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06375-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10067-023-06768-5","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-023-06768-5","URL":"https:\/\/doi.org\/10.1007\/s10067-023-06768-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the UCLA institutional review board (IRB#10\u2013001833).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Dr. Charles-Schoeman received\u00a0grants from Pfizer, Bristol-Meyers Squibb, AbbVie, and consulting fees from Pfizer, AbbVie, Regneron-Sanofi, and Gilead. Other authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}